CSIMarket Company Name, Ticker, Suppliers, else..
 
Os Therapies Incoporated  (NYSEAMER: OSTX)
Other Ticker:  
 
 
Price: $1.6800 $0.00 0.000%
Day's High: $1.72 Week Perf: -1.18 %
Day's Low: $ 1.63 30 Day Perf: -7.69 %
Volume (M): 410 52 Wk High: $ 7.00
Volume (M$): $ 688 52 Wk Avg: $2.48
Open: $1.66 52 Wk Low: $1.12



 Market Capitalization (Millions $) 36
 Shares Outstanding (Millions) 21
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

Os Therapies Incoporated


   Company Address: 115 Pullman Crossing Road Grasonville 21638 MD
   Company Phone Number: 297-7793   Stock Exchange / Ticker: NYSEAMER OSTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.18%    
ABT   -6.33%    
BMY        0.04% 
JNJ        4.39% 
MRK   -4.43%    
PFE   -3.47%    
• View Complete Report
   



Cnbx Pharmaceuticals Inc

Cnbx Pharmaceuticals Inc reported operating loss of $-0.04038 million, in the most recent fiscal period

The stockholders haven't hoped for some changes at the top-line during the the earnings cycle of fiscal March to May 31 2025 at the Cnbx Pharmaceuticals Inc . But, they monitor the Major Pharmaceutical Preparations company's operating loss that was at $-0.04038 million, in the same period.

Lexaria Bioscience Corp

Lexaria Bioscience Corp declared extraordinary recent numbers, in the most recent fiscal period

LEXX announced very robust Revenue improvement of 107.143 % year on year to $0.17 million in the most recent fiscal period, but increased a loss per share at $-0.21. On the other hand the LEXXs' top-line gain have been below the 264.34% relative to the comparable period a year ago, reported by remainder of the Major Pharmaceutical Preparations sector.

Kalvista Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc , reduction in the corporate performance during the fourth quarter of 2025 earnings season

The Major Pharmaceutical Preparations sector advisors begin to scrutinize the fourth quarter of 2025 numbers. Now they monitor operating shortfall of $-55.029 million, from the KALV, which hasn't cited any revenue yet, for the respective February to April 30 2025 reporting period.

Nurix Therapeutics Inc

A Blowout results, by Nurix Therapeutics Inc during the fiscal three months ending May 31 2025

For the financial second quarter of 2025 Nurix Therapeutics Inc decreased a loss per share of $-0.52 per share compare to $-0.71 a year prior and EPS improved from $-0.67 per share from the prior reporting period. The revenue surged sharply by 264.34 % to $44.06 million from $12.09 million in the similar reporting period a year prior and sequentially Revenue doubled by 138.747 % from $18.45 million.

Exicure Inc

Exicure Inc has Turned into Profitability at the Exicure Inc in fiscal interval ending March 31 2025

For the fiscal interval ending March 31 2025 XCUR had turn a round to earnings by displaying earnings per share of $0.49 per share compare to $-0.10 a year before and income per share turned positive from $-0.83 per share from the previous reporting period. The revenue remained unchanged to $0.00 million from $0.50 million in the same reporting period a year before and sequentially from $0.00 million.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com